Medtronic gains US first for heart failure device
This article was originally published in Clinica
Executive Summary
Medtronic has won the race to become the first company to gain US market approval for a cardiac resynchronisation device for treating congestive heart failure (CHF). The FDA's decision to sanction the InSync biventricular cardiac pacing system signals a new era in device-based solutions for patients in the US who are suffering from moderate to severe heart failure.